Lupin Ltd: Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla

Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla Agreement enables expanded patient access of the only EU-approved treatment for myotonia symptoms in non-dystrophic myotonic

Related Keywords

Germany ,Mmedis ,Poitou Charentes ,France ,Mumbai ,Maharashtra ,India ,Hungary ,United Kingdom ,Croatia ,Slovenia ,South Africa ,Czech Republic ,Thierry Volle ,Martina Perharic ,Asia Pacific ,Shweta Munjal ,Linkedin ,Lupin Limited ,Twitter ,Corporate Communications ,Biotechnology Pharmaceuticals ,Facebook ,Consilium Strategic Communications ,Lupin Signs Distribution Agreement ,Orphan Drug Namuscla ,Eastern European ,East European ,Eastern Europe ,Myotonic Disorders ,Non Dystrophic Myotonias ,Latin America ,Middle East ,Great Place ,Global Head ,Managing Director Corporate Communications ,Neuromuscular Discord ,Muscle Nerve ,Lupin ,Signs ,Distribution ,Agreement ,Orphan ,Drug ,Namuscla ,